Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
Dey President Carolyn Myers, Ph.D., said: "We are very pleased to be launching Dey's highly anticipated next-generation, needle-protected EpiPen Auto-Injector. The objective of the product's new features is to give those who carry an epinephrine auto injector some additional peace of mind when it comes to the risk of anaphylaxis. We also hope that those who are at risk of anaphylaxis but currently don't carry an epinephrine auto injector will become as prepared as possible for the risk of allergen exposure."
EpiPen Auto-Injector is the number one prescribed first-line emergency auto-injector for potentially life-threatening allergic reactions known as anaphylaxis. Anaphylaxis can occur when people with allergies to food, insect stings, latex or other allergens come in contact with that allergen. Immediate access to epinephrine is critical during the first few minutes of an anaphylactic reaction.
"Prompt administration of epinephrine during a severe allergic reaction helps save lives so it's important that people not only have immediate access to a self-injected epinephrine but know how to properly use it," said Dr. Phil Lieberman, Clinical Professor of Medicine and Pediatrics, University of Tennessee College of Medicine. "This new EpiPen Auto-Injector offers enhancements to make it easier for people to administer epinephrine quickly and properly in an emergency situation."